These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16955281)

  • 1. Nephrotoxicity with cyclooxygenase 2 inhibitor use in children.
    Fletcher JT; Graf N; Scarman A; Saleh H; Alexander SI
    Pediatr Nephrol; 2006 Dec; 21(12):1893-7. PubMed ID: 16955281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib.
    Rocha JL; Fernández-Alonso J
    Lancet; 2001 Jun; 357(9272):1946-7. PubMed ID: 11425419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephrotoxicity of selective COX-2 inhibitors.
    Woywodt A; Schwarz A; Mengel M; Haller H; Zeidler H; Köhler L
    J Rheumatol; 2001 Sep; 28(9):2133-5. PubMed ID: 11550988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Renal tolerance of selective inhibitors of cyclooxygenase type 2].
    Deray G
    Presse Med; 2001 Oct; 30(30):1507-12. PubMed ID: 11712212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Case report: reversible acute renal failure following therapy with both ketorolac (non-selective non-steroidal anti-inflammatory drug NSAID) and celecoxib (COX-2 selective) in the same patient].
    Galli G; Panzetta G
    G Ital Nefrol; 2002; 19(2):199-203. PubMed ID: 12195419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Assessment of the number of cardio- and cerebrovascular events due to rofecoxib (Vioxx) in Germany between 2001 and 2004].
    Sawicki PT; Bender R; Selke GW; Klauber J; Gutschmidt S
    Med Klin (Munich); 2006 Mar; 101(3):191-7. PubMed ID: 16648975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal papillary necrosis induced by naproxen.
    Kovacevic L; Bernstein J; Valentini RP; Imam A; Gupta N; Mattoo TK
    Pediatr Nephrol; 2003 Aug; 18(8):826-9. PubMed ID: 12774222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prothrombotic effect of Rofecoxib in a murine venous thrombosis model.
    Nagai N; Hoylaerts MF; Gallacher DJ; Lu HR; Lijnen HR
    Thromb Res; 2008; 122(5):668-73. PubMed ID: 18571222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia?
    Barozzi N; Tett SE
    Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1184-91. PubMed ID: 17636557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAids.
    Mason RP; Walter MF; Day CA; Jacob RF
    Subcell Biochem; 2007; 42():175-90. PubMed ID: 17612051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tubulointerstitial nephritis associated with treatment with selective Cox-2 inhibitors, celecoxib and rofecoxib].
    Ortiz M; Mon C; Fernández MJ; Sánchez R; Mampaso F; Alvarez Ude F
    Nefrologia; 2005; 25(1):39-43. PubMed ID: 15789535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
    J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclooxygenase 1 and/or 2 blockade ameliorates the renal tissue damage triggered by ischemia and reperfusion injury.
    Feitoza CQ; Câmara NO; Pinheiro HS; Gonçalves GM; Cenedeze MA; Pacheco-Silva A; Santos OF
    Int Immunopharmacol; 2005 Jan; 5(1):79-84. PubMed ID: 15589463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eosinophilic tubulointerstitial nephritis on treatment with isotretinoin.
    Kaya Aksoy G; Koyun M; Akkaya B; Comak E; Gemici A; Akman S
    Eur J Pediatr; 2016 Dec; 175(12):2005-2006. PubMed ID: 27629781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome.
    Reinalter SC; Jeck N; Brochhausen C; Watzer B; Nüsing RM; Seyberth HW; Kömhoff M
    Kidney Int; 2002 Jul; 62(1):253-60. PubMed ID: 12081585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients.
    Vogt L; de Zeeuw D; Woittiez AJ; Navis G
    Nephrol Dial Transplant; 2009 Apr; 24(4):1182-9. PubMed ID: 19037084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rofecoxib (Vioxx), a specific cyclooxygenase-2 inhibitor, is chemopreventive in a mouse model of colon cancer.
    Evans JF
    Am J Clin Oncol; 2003 Aug; 26(4):S62-5. PubMed ID: 12902858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Renal protective effects of specific cyclooxygenase-2 inhibitor in rats with subtotal renal ablation].
    Kong WX; Ma J; Gu Y; Yang HC; Zuo YQ; Lin SY
    Zhonghua Nei Ke Za Zhi; 2003 Mar; 42(3):186-90. PubMed ID: 12816702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Coxibs: cyclooxygenase-2 inhibitors].
    Turnheim K
    Wien Klin Wochenschr; 2001 Aug; 113(15-16):558-65. PubMed ID: 11571832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Celecoxib, a selective cyclooxygenase-2 inhibitor, attenuates renal injury in a rat model of Cisplatin-induced nephrotoxicity.
    Suddek GM; El-Kenawi AE; Abdel-Aziz A; El-Kashef HA
    Chemotherapy; 2011; 57(4):321-6. PubMed ID: 21893983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.